US FDA probes cognitive impact of new cholesterol drugs; Regeneron, Sanofi …

US FDA probes cognitive impact of new cholesterol drugs; Regeneron, Sanofi …

The Sanofi statement repeated a filing made by Regeneron last month, in which the company said it had been advised by the FDA that the agency had become aware of neurocognitive adverse events associated with an experimental class of drugs known as 

6
Like
Save

Comments

Write a comment

*